Современные подходы к вакцинации больных с ревматическими заболеваниями

Белов Б.С., Тарасова Г.М., Муравьева Н.В. Современные подходы к вакцинации больных с ревматическими заболеваниями. Терапевтический архив. 2021; 93 (5): 622–627.
DOI: 10.26442/00403660.2021.05.200794

________________________________________________

Belov BS, Tarasova GM, Muravyeva NV. Modern approaches to immunization of patients of rheumatologic profile. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (5): 622–627. DOI: 10.26442/00403660.2021.05.200794

Читать PDF

Аннотация

За последнее время в ревматологии существенно увеличилась значимость коморбидных инфекций, оказывающих существенное влияние на морбидность и летальность, особенно при иммуновоспалительных ревматических заболеваниях (ИВРЗ). В связи с этим все большее значение в профилактике инфекций у этих больных уделяется вакцинации. В настоящем обзоре представлен обновленный вариант рекомендаций по вакцинации взрослых больных с ИВРЗ, подготовленный экспертами Европейской антиревматической лиги. Отмечается низкий (субоптимальный) охват вакцинацией указанных пациентов отчасти по причине низкой частоты направления со стороны врачей. Подчеркивается роль ревматологического консилиума в решении проблем, связанных с иммунизацией больных с ИВРЗ, а также важность совместного принятия решений с учетом потребностей и предпочтения пациентов. Рассмотрены вопросы, касающиеся применения вакцин против гриппа, пневмококковой инфекции, гепатита В, герпеса и папилломы человека у ревматологических больных.

Ключевые слова: иммуновоспалительные ревматические заболевания, инфекции, грипп, пневмония, вирус папилломы человека, вакцинация, рекомендации

________________________________________________

Recently, the importance of comorbid infections in rheumatology has increased significantly, which have a significant impact on morbidity and mortality, especially in immuno-inflammatory rheumatic diseases (IIRD). In this regard, vaccination is becoming increasingly important in the prevention of infections in these patients. This review presents an updated version of the recommendations for vaccination of adult patients with IIRD, prepared by experts of the European Union League against Rheumatism (EULAR). There is a low (suboptimal) vaccination coverage of these patients, partly due to the low frequency of referral by doctors. The role of the rheumatology team in solving the problems associated with immunization of patients with IIRD is emphasized, as well as the importance of joint decision-making taking into account the needs and preferences of patients. The issues concerning the use of vaccines against influenza, pneumococcal infection, hepatitis b, herpes and human papilloma in rheumatologic patients are considered.

Keywords: immuno-inflammatory rheumatic diseases, infections, influenza, pneumonia, human papilloma virus, vaccination, guidelines

Список литературы

1. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. DOI:10.1136/annrheumdis-2019-215882
2. Qendro T, de la Torre ML, Panopalis P, et al. Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. J Rheumatol. 2020;47(5):770-7. DOI:10.3899/jrheum.181376
3. Subesinghe S, Rutherford AI, Ibrahim F, et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016;17:322. DOI:10.1186/s12891-016-1187-4
4. Ribeiro AC, Guedes LK, Moraes JC, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011;70:2144-7. DOI:10.1136/ard.2011.152983
5. Наумцева М.С., Белов Б.С., Александрова Е.И., и др. Иммуногенность и безопасность 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом: результаты двухлетнего наблюдения. Научно-практическая ревматология. 2016;54(6):674-80 [Naumtseva MS, Belov BS, Aleksandrova EN, et al. Immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatoid arthritis: results of a two-year follow-up study. Rheumatology Science and Practice. 2016;54(6):674-80 (in Russian)]. DOI:10.14412/1995-4484-2016-674-680
6. Тарасова Г.М., Белов Б.С., Буханова Д.В., и др. Изучение иммуногенности и безопасности 23-валентной полисахаридной пневмококковой вакцины у больных системной красной волчанкой.Научно-практическая ревматология. 2018;56(4):433-8 [Tarasova GM, Belov BS, Bukhanova DV, et al. Investigation of immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus. Rheumatology Science and Practice. 2018;56(4):433-8 (in Russian)]. DOI:10.14412/1995-4484-2018-433-438
7. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158. DOI:10.1186/1471-2474-13-158
8. Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(5):359-65. DOI:10.3109/03009742.2012.670729
9. Bello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299-306. DOI:10.4081/reumatismo.2012.299
10. Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016;6:37817. DOI:10.1038/srep37817
11. Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol. 2013;42(6):445-50.
DOI:10.3109/03009742.2013.788733
12. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75-81. DOI:10.1002/art.25033
13. Nakafero G, Grainge MJ, Myles PR, et al. Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink. Ann Rheum Dis. 2019;78(8):1122-6. DOI:10.1136/annrheumdis-2019-215086
14. Bukhanova D, Belov B, Tarasova G, et al. Assessment of efficacy, safety and immunogenicity of a trivalent split-virusi nfluenza vaccine in patients with rheumatic diseases. Ann Rheum Dis. 2019:78(6 Suppl. 2):A676. DOI:10.1136/annrheumdis-2019-eular.3663
15. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. DOI:10.1093/ofid/ofu024
16. Wolfe F, Mitchell DM, Sibley JT. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481-94.
17. Koivuniemi R, Leirisalo-Repo M, Suomalainen R, et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol. 2006;35:273-6.
18. Nossent J, Cices N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus. 2007;16:309-17
19. Narata R, Wangkaew S, Kasitanon N, Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Public Health. 2007;38(3):528-36
20. Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011;70(7):1289-91. DOI:10.1136/ard.2010.144451
21. Bingham CO 3rd, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818-22. DOI:10.1136/annrheumdis-2013-204427
22. Rezende RP, Ribeiro FM, Albuquerque EM, et al. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus. 2016;25:1254-9. DOI:10.1177/0961203316636472
23. Winthrop KL, Bingham CO 3rd, Komocsar WJ, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019;21(1):102.
DOI:10.1186/s13075-019-1883-1
24. Tarasova G, Belov B, Bukhanova D, et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: the relationship of immunogenicity with therapy. Ann Rheum Dis. 2019;78(6 Suppl. 2):A785.
DOI:10.1136/annrheumdis-2019-eular.3646
25. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-9
26. Чучалин А.Г., Брико Н.И., Авдеев С.Н., и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34 [Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019;29(1):19-34 (in Russian)]. DOI:10.18093/0869-0189-2019-29-1-19-34
27. Kapetanovic CM, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013;15(1):R1. DOI:10.1186/ar4127
28. Kapetanovic СМ, Nagel J, Nordström I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;35(6):903-8. DOI:10.1016/j.vaccine.2016.12.068
29. Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72:1037-43. DOI:10.1136/annrheumdis-2011-201270
30. Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo- controlled randomized double-blind study. Vaccine. 2017;35(37):4877-85. DOI:10.1016/j.vaccine.2017.07.094
31. Elkayam O, Ablin J, Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev. 2007;6(5):312-4.
32. Bukhanova D, Belov B, Tarasova G, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis. 2019;78(6 Suppl. 2):A336. DOI:10.1136/annrheumdis-2019-eular.3173
33. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-18. DOI:10.1093/cid/cit816
34. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-9. DOI:10.1001/jama.2012.7304
35. Yun H, Xie F, Baddley JW, et al. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. J Rheumatol. 2017;44(7):1083-7. DOI:10.3899/jrheum.160685
36. Baumrin E, Van Voorhees A, Garg A, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019;81(1):102-10.
37. Pileggi GS, Da Mota LMH, Kakehasi AM, et al. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Adv Rheumatol. 2019;59(1):17.
DOI:10.1186/s42358-019-0056-x
38. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485-91. DOI:10.1177/0961203310372952
39. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659-64. DOI:10.1136/annrheumdis-2012-201393
40. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016;151:110-9. DOI:10.1053/j.gastro.2016.04.002
41. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-33. DOI:10.1136/annrheumdis-2017-212196
42. Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine. 2016;83(3):341-3.
DOI:10.1016/j.jbspin.2015.07.004
43. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-92. DOI:10.1016/j.cgh.2012.11.011
44. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-8.DOI:10.1111/j.1365-2036.2011.04617.x
45. Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010;49:2225-7. DOI:10.1093/rheumatology/keq185
46. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810. DOI:10.1136/annrheumdis-2015-208840

________________________________________________

1. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. DOI:10.1136/annrheumdis-2019-215882
2. Qendro T, de la Torre ML, Panopalis P, et al. Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. J Rheumatol. 2020;47(5):770-7. DOI:10.3899/jrheum.181376
3. Subesinghe S, Rutherford AI, Ibrahim F, et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016;17:322. DOI:10.1186/s12891-016-1187-4
4. Ribeiro AC, Guedes LK, Moraes JC, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011;70:2144-7. DOI:10.1136/ard.2011.152983
5. Naumtseva MS, Belov BS, Aleksandrova EN, et al. Immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatoid arthritis: results of a two-year follow-up study. Rheumatology Science and Practice. 2016;54(6):674-80 (in Russian) DOI:10.14412/1995-4484-2016-674-680
6. Tarasova GM, Belov BS, Bukhanova DV, et al. Investigation of immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus. Rheumatology Science and Practice. 2018;56(4):433-8 (in Russian)
DOI:10.14412/1995-4484-2018-433-438
7. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158. DOI:10.1186/1471-2474-13-158
8. Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(5):359-65. DOI:10.3109/03009742.2012.670729
9. Bello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299-306. DOI:10.4081/reumatismo.2012.299
10. Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016;6:37817. DOI:10.1038/srep37817
11. Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol. 2013;42(6):445-50.
DOI:10.3109/03009742.2013.788733
12. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75-81. DOI:10.1002/art.25033
13. Nakafero G, Grainge MJ, Myles PR, et al. Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink. Ann Rheum Dis. 2019;78(8):1122-6. DOI:10.1136/annrheumdis-2019-215086
14. Bukhanova D, Belov B, Tarasova G, et al. Assessment of efficacy, safety and immunogenicity of a trivalent split-virusi nfluenza vaccine in patients with rheumatic diseases. Ann Rheum Dis. 2019:78(6 Suppl. 2):A676. DOI:10.1136/annrheumdis-2019-eular.3663
15. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. DOI:10.1093/ofid/ofu024
16. Wolfe F, Mitchell DM, Sibley JT. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481-94.
17. Koivuniemi R, Leirisalo-Repo M, Suomalainen R, et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol. 2006;35:273-6.
18. Nossent J, Cices N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus. 2007;16:309-17
19. Narata R, Wangkaew S, Kasitanon N, Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Public Health. 2007;38(3):528-36
20. Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011;70(7):1289-91. DOI:10.1136/ard.2010.144451
21. Bingham CO 3rd, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818-22. DOI:10.1136/annrheumdis-2013-204427
22. Rezende RP, Ribeiro FM, Albuquerque EM, et al. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus. 2016;25:1254-9. DOI:10.1177/0961203316636472
23. Winthrop KL, Bingham CO 3rd, Komocsar WJ, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019;21(1):102.
DOI:10.1186/s13075-019-1883-1
24. Tarasova G, Belov B, Bukhanova D, et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: the relationship of immunogenicity with therapy. Ann Rheum Dis. 2019;78(6 Suppl. 2):A785.
DOI:10.1136/annrheumdis-2019-eular.3646
25. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-9
26. Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019;29(1):19-34 (in Russian) DOI:10.18093/0869-0189-2019-29-1-19-34
27. Kapetanovic CM, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013;15(1):R1. DOI:10.1186/ar4127
28. Kapetanovic СМ, Nagel J, Nordström I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;35(6):903-8. DOI:10.1016/j.vaccine.2016.12.068
29. Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72:1037-43. DOI:10.1136/annrheumdis-2011-201270
30. Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo- controlled randomized double-blind study. Vaccine. 2017;35(37):4877-85. DOI:10.1016/j.vaccine.2017.07.094
31. Elkayam O, Ablin J, Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev. 2007;6(5):312-4.
32. Bukhanova D, Belov B, Tarasova G, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis. 2019;78(6 Suppl. 2):A336. DOI:10.1136/annrheumdis-2019-eular.3173
33. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-18. DOI:10.1093/cid/cit816
34. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-9. DOI:10.1001/jama.2012.7304
35. Yun H, Xie F, Baddley JW, et al. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. J Rheumatol. 2017;44(7):1083-7. DOI:10.3899/jrheum.160685
36. Baumrin E, Van Voorhees A, Garg A, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019;81(1):102-10.
37. Pileggi GS, Da Mota LMH, Kakehasi AM, et al. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Adv Rheumatol. 2019;59(1):17.
DOI:10.1186/s42358-019-0056-x
38. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485-91. DOI:10.1177/0961203310372952
39. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659-64. DOI:10.1136/annrheumdis-2012-201393
40. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016;151:110-9. DOI:10.1053/j.gastro.2016.04.002
41. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-33. DOI:10.1136/annrheumdis-2017-212196
42. Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine. 2016;83(3):341-3.
DOI:10.1016/j.jbspin.2015.07.004
43. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-92. DOI:10.1016/j.cgh.2012.11.011
44. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-8.DOI:10.1111/j.1365-2036.2011.04617.x
45. Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010;49:2225-7. DOI:10.1093/rheumatology/keq185
46. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810. DOI:10.1136/annrheumdis-2015-208840

Авторы

Б.С. Белов*, Г.М. Тарасова, Н.В. Муравьева

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия
*belovbor@yandex.ru

________________________________________________

Boris S. Belov*, Galina M. Tarasova, Natalia V. Muravyeva

Nasonova Research Institute of Rheumatology, Moscow, Russia
*belovbor@yandex.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.